Apellis Pharmaceuticals (APLS) PT Set at $53.00 by Cantor Fitzgerald
Other equities research analysts have also recently issued reports about the stock. B. Riley raised their price objective on shares of Apellis Pharmaceuticals from $27.00 to $40.00 and gave the stock a buy rating in a research report on Thursday, September 13th. ValuEngine upgraded shares of Apellis Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, November 1st. Zacks Investment Research upgraded shares of Apellis Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, October 8th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Apellis Pharmaceuticals from $38.00 to $34.00 and set an overweight rating for the company in a research report on Wednesday, November 14th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Apellis Pharmaceuticals has an average rating of Buy and an average price target of $38.67.
Shares of NASDAQ APLS opened at $17.99 on Monday. The stock has a market capitalization of $1.02 billion and a PE ratio of -4.90. The company has a quick ratio of 14.91, a current ratio of 14.90 and a debt-to-equity ratio of 0.14. Apellis Pharmaceuticals has a 52 week low of $11.45 and a 52 week high of $32.00.
In other news, major shareholder Morningside Venture Investment acquired 140,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 19th. The stock was purchased at an average cost of $18.34 per share, for a total transaction of $2,567,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel David O. Watson sold 15,776 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $18.78, for a total transaction of $296,273.28. The disclosure for this sale can be found here. 9.30% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can acquired a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at about $107,000. Legal & General Group Plc increased its position in shares of Apellis Pharmaceuticals by 186.1% during the second quarter. Legal & General Group Plc now owns 5,385 shares of the company’s stock valued at $118,000 after acquiring an additional 3,503 shares during the last quarter. PNC Financial Services Group Inc. acquired a new stake in shares of Apellis Pharmaceuticals during the second quarter valued at about $162,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at about $192,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Apellis Pharmaceuticals during the second quarter valued at about $247,000. Hedge funds and other institutional investors own 55.94% of the company’s stock.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Featured Story: Bear Market – How and Why They Occur
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.